English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, August 19, 2021
華領醫藥公佈2021年中期業績
Hua Medicine Announces 2021 Interim Results
Friday, April 23, 2021
华领医药糖尿病首创新药多扎格列艾汀NDA获NMPA受理!为全球首个葡萄糖激酶激活剂
華領醫藥糖尿病首創新藥多扎格列艾汀NDA獲NMPA受理!為全球首個葡萄糖激酶激活劑
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally
Friday, March 19, 2021
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission
华领医药公布2020年全年业绩
華領醫藥公佈2020年全年業績
Friday, December 18, 2020
华领医药成功完成III期注册临床研究 公布多扎格列艾汀与二甲双胍联合用药临床试验DAWN研究(HMM0302)的52周结果
華領醫藥成功完成III期註冊臨床研究 公佈多扎格列艾汀與二甲雙胍聯合用藥臨床試驗DAWN研究(HMM0302)的52週結果

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575